Deadly Cardiac Arrest Risk Hidden From Dialysis Patients
In November 2011, Fresenius Medical Care, the leading supplier of dialysis machines and disposable products, documented cardiac injury risks linked to its products GranuFlo and NaturaLyte in an internal memo. Then the company kept the information hidden from the public until the document was anonymously leaked to the FDA in March 2012.
What Fresenius didn’t tell you is that patients who undergo GranuFlo dialysis face a 6-8x increased risk of suffering heart injury or death.
Furthermore, the company documented that 941 people suffered cardiac arrest in their facilities in 2010 alone. That doesn’t even account for cardiac injuries and deaths among those who received GranuFlo treatment in other clinics.
If you or your loved one suffered cardiac arrest, or someone you know sustained a fatal heart injury after receiving dialysis treatment with GranuFlo or NaturaLyte, you deserve compensation. Contact us today to tell us your story, and we’ll explain your legal rights and options.
FDA Recalls Deadly Dialysis Products
In June 2012, the FDA issued a Class I Recall of GranuFlo and NaturaLyte. The FDA recall occurred 7 months after Fresenius discovered the link between GranuFlo and heart injuries and failed to report the risk to patients, doctors and the FDA.
What You Need to Know
- Most incidents of cardiac arrest occur within 48 hours of receiving GranuFlo dialysis treatment. The majority result in death.
- GranuFlo was used in more than 1,800 Fresenius clinics across the country. The facilities may have different names, so contact us to find out if your clinic is affiliated with Fresenius.
- Granuflo was also sold to clinics not owned by Fresenius. These clinics were not warned of heart injury risks by Fresenius’ November 2011 internal memo, according to the New York Times.
Contact us today for a free consultation. If you choose to pursue compensation, we will build a powerful case on your behalf.